Clinical Trial Update: Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating safety and superior effectiveness of cysteamine bitartrate delayed-release capsules (RP103) in Cystinosis has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• RP103 (cysteamine bitartrate delayed-release capsules) (cysteamine bitartrate delayed-release)

Snippet

Sponsor: Amgen | Conditions: Cystinosis | Phase 3 | Status: COMPLETED | Results posted: 2017-05-24